Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Leroy Hood, Frederick Hawthorne, Susan Evans, Mike Aicher

Premium

US President Barack Obama has named Institute for Systems Biology president Leroy Hood and Frederick Hawthorne, director of the Institute of Nano and Molecular Medicine at the University of Missouri at Columbia, as two of the 12 new winners of its National Medal of Science awards.


Susan Evans has been appointed to Venaxis' board of directors. She is vice president of scientific affairs for Danaher's Beckman Coulter division. She has held various positions at Beckman Coulter, including as vice president of corporate strategic planning, and vice president/general manager of Beckman Coulter Genomics. She holds a PhD in chemistry from the University of Detroit.


Omicia has appointed Mike Aicher to CEO and to the company's board of directors, taking over for Martin Reese, a co-founder of the company. Reese is now Omicia's president and chief scientific officer. Previously, Aicher was CEO of the National Genetics Institute, a company that he co-founded that became a wholly owned subsidiary of Laboratory Corporation of America. Most recently, he led LabCorp's western division and was responsible for the company's esoteric business units. He holds a BS in business administration from the University of Redlands and an MBA in economics from Columbus University.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.